Results 71 to 80 of about 6,478 (160)

Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019

Viruses
Although the coronavirus disease 2019 (COVID-19) pandemic is coming to an end, it still poses a threat to the immunocompromised and others with underlying diseases. Especially in cases of persistent COVID-19, new mutations conferring resistance to severe
Chie Yamamoto, Masashi Taniguchi, Keitaro Furukawa, Toru Inaba, Yui Niiyama, Daisuke Ide, Shinsuke Mizutani, Junya Kuroda, Yoko Tanino, Keisuke Nishioka, Yohei Watanabe, Koichi Takayama, Takaaki Nakaya, Yoko Nukui   +13 more
doaj   +1 more source

Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients

Infection and Drug Resistance
Na Chen,1,2 Xuben Yu,3 Lu Li,1 Ping Yang,1 Rong Dong,1,4 Yizhen Huang,1,5 Xiao Ling,1,6 Qiaoqiao Shentu,1,7 Wenqiao Yu,8 Saiping Jiang1 1Department of Clinical Pharmaceutical, The First Affiliated Hospital of Zhejiang University School of Medicine ...
Chen N, Yu X, Li L, Yang P, Dong R, Huang Y, Ling X, Shentu Q, Yu W, Jiang S   +9 more
doaj  

Deriving M-polynomial Based Topological Descriptors of Oral Antiviral Clinical Drug Nirmatrelvir

Scientific Annals of Computer Science
The novel human coronavirus known as SARS-CoV-2 poses a serious risk to human health. Regretfully, the US Food and Drug Administration (FDA) has approved very few oral antiviral medications for the treatment of COVID-19 patients. In the current study, we
Shibsankar Das, Modhuleena Mandal
doaj   +1 more source

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?

Molecular Therapy: Nucleic Acids, 2023
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, Sang-Soo Lee, Chiranjib Chakraborty   +4 more
doaj   +1 more source

SARS-CoV-2 Drug-Resistant Mutations in Non-Structural Proteins. [PDF]

Viruses
Shaw M, Fehr AR.
europepmc   +1 more source

The Combination of Nirmatrelvir and Ivermectin Exerts Strongly Synergistic Antiviral and Anti-Inflammatory Effects Against Murine Coronavirus Infection of Macrophages. [PDF]

Int J Mol Sci
How WZY, Teh LX, Chow VTK.
europepmc   +1 more source

Evaluating the Effectiveness of Antivirals for COVID-19 in the Post-vaccine, Omicron Era: A Systematic Review and Meta-analysis. [PDF]

Open Forum Infect Dis
Edwards LJ, Liu B, Wood JG, Stephens N, Cheng AC.   +4 more
europepmc   +1 more source

Treatment of acute COVID-19 in the community. [PDF]

Aust Prescr
Milliken E.
europepmc   +1 more source

Heat Shock Protein Inhibitor Tanespimycin (17AAG) Suppresses SARS-CoV-2 Main Protease Activity and Is More Potent Than Clinically Approved Antiviral Nirmatrelvir. [PDF]

Chembiochem
Mukherjee G, Chakraborty S, Chandra A, Chowdhury G, Chakrabarty A.   +4 more
europepmc   +1 more source

Mutation-Aware Machine Learning Framework for Predicting Binding Affinity of Nirmatrelvir Analogs Targeting Coronavirus Main Proteases. [PDF]

Molecules
Rahman MS, Hasan MM, M Islam S.
europepmc   +1 more source